Drug updated on 4/17/2024
| Dosage Form | Implant (subcutaneous; 10.8 mg) |
| Drug Class | Gonadotropin-releasing hormone agonists |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for use in combination with flutamide for the management of locally confined carcinoma of the prostate.
- Indicated for use as palliative treatment of advanced carcinoma of the prostate.
Summary
- Goserelin (Zoladex) is indicated for use in combination with flutamide for the management of locally confined carcinoma of the prostate and as a palliative treatment of advanced carcinoma of the prostate.
- The study reviewed was a systematic review/meta-analysis that compared goserelin (Zoladex), among other gonadotropin-releasing hormone (GnRH) agonists, to GnRH antagonists such as Degarelix and relugolix in terms of their impact on cardiovascular events in men with prostate cancer.
- According to this study, recipients of GnRH antagonists had lower risk ratios for adverse cardiovascular events, cardiovascular death, and all-cause mortality than those receiving GnRH agonists like Zoladex. This suggests that individuals at high risk or having underlying cardiovascular conditions may benefit from using GnRH antagonists.
- While effectiveness outcomes were not directly discussed within this study, it implies that these drugs are used comparably for treating prostate cancer, suggesting similar levels of effectiveness between them. However, without direct evidence, definitive conclusions cannot be drawn regarding comparative efficacy.
- Methodological limitations noted include short follow-up periods, unblinded study designs, and reliance on safety reporting mechanisms for identifying adverse cardiac events, indicating the need for further research with a rigorous design before drawing definitive conclusions about the relative safety profiles of these medications.
- The findings from this study apply broadly to men with prostate cancer but suggest potential subgroup considerations where individuals with a history or high-risk factors related to heart disease could potentially benefit more from using a GnRH antagonist over an agonist like Zoladex.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Zoladex (goserelin) Prescribing Information. | 2020 | TerSera Therapeutics LLC, Deerfield, IL |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| The cardiovascular effects of gonadotropin-releasing hormone antagonists in men with prostate cancer. | 2022 | European Heart Journal - Cardiovascular Pharmacotherapy |